NTLA logo

NTLA
Intellia Therapeutics Inc

14,950
Mkt Cap
$1.76B
Volume
3.2M
52W High
$28.25
52W Low
$6.83
PE Ratio
-3.57
NTLA Fundamentals
Price
$12.60
Prev Close
$12.37
Open
$12.40
50D MA
$13.56
Beta
1.75
Avg. Volume
6.66M
EPS (Annual)
-$3.81
P/B
2.44
Rev/Employee
$179,498.67
$617.75
Loading...
Loading...
News
all
press releases
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
News Placeholder
More News
News Placeholder
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +11.60% and -3.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Key PointsArk Invest added to existing positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday...
News Placeholder
NTLA Q2 EPS Increased by Brookline Capital Markets
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at Brookline Capital Markets upped their Q2 2026 EPS estimates for Intellia Therapeutics in a report released on Wednesday, April 29th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.75...
News Placeholder
Cathie Wood buys $14.1 million of megacap tech stock
Cathie Wood, chief of Ark Investment Management, often trades during earnings season.This time, the timing worked. She picked up shares of a megacap tech company just before results, and the stock...
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available